Tuhura Biosciences Inc (HURA)

$0.47 -0.05 (-10.04%)
Market Cap 27.43M
Revenue (ttm) 0.00
Net Income (ttm) -21.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,492,800
Avg Vol 862,178
Day's Range N/A - N/A
Shares Out 51.26M
Stochastic %K 17%
Beta 0.03
Analysts Strong Sell
Price Target $8.62

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology
Sector: Healthcare
Phone: 813 875 6600
Address:
10500 University Center Drive, Suite 110, Tampa, United States
hiletsmakesomemoneyy
hiletsmakesomemoneyy Feb. 4 at 1:04 AM
$HURA Hi brother, not sure what’s your beef with this stock, maybe you are stuck from long time. But let me be very clear, these biotech stock are more of coin flip. Random morning, you are gonna see them pop. Just hold on. I know people like you, will abuse these comments n all. But it’s fine. Our patience is the key to this stock
0 · Reply
hiletsmakesomemoneyy
hiletsmakesomemoneyy Feb. 4 at 1:00 AM
$HURA this is where you have to wait. It’s really a great PR that they released. It takes a week or two to digest among real people.
0 · Reply
Ren_Stimpy
Ren_Stimpy Feb. 3 at 9:07 PM
$HURA Nice!! bought at .4258 and sold for .4660 for a nice 10% profit. Honestly! Was a little nervous at first. When Short sellers are in control they like for SP to be right at 9.9% so they don’t trigger SSR. They failed but still not holding overnight!! Good luck to you all!
0 · Reply
drkazmd65
drkazmd65 Feb. 3 at 8:54 PM
$HURA - Started a small position here this morning,.... Luckily after the 10-11% drop. Obviously, any small pharma that's still got some time to run out on the clinical trials is risky. Sounds like they should have some answers about the candidates and trials sometime during the next year or so,... In the meantime, we wait.
0 · Reply
P_etheris
P_etheris Feb. 3 at 7:37 PM
$HURA Oh, I fooked up on this one… Assessing situation 🤔 First stock in 12 months I bought too high 🤦🏻‍♂️
1 · Reply
TuHURA_IR
TuHURA_IR Feb. 3 at 7:03 PM
$HURA TuHURA Biosciences has received FDA Orphan Drug Designation for IFx 2.0 in the treatment of Stage IIB to Stage IV cutaneous melanoma. This designation reflects the FDA’s recognition of the unmet medical need in this patient population and the potential clinical relevance of IFx 2.0. Orphan Drug Designation provides regulatory incentives that can support development efficiency, including market exclusivity and potential fee reductions. Importantly, this milestone strengthens the regulatory foundation of the IFx platform while Phase 3 development continues in Merkel cell carcinoma. Together, these advances reinforce TuHURA’s strategy of building value through disciplined clinical execution and regulatory alignment.
0 · Reply
TU6637
TU6637 Feb. 3 at 6:51 PM
$HURA they say that all the time On repeat 😂
1 · Reply
michpetr
michpetr Feb. 3 at 5:42 PM
$HURA how could the analysts value this at $10 is beyond my imagination... this runs for r/s.....
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Feb. 3 at 5:30 PM
$HURA
1 · Reply
Love1010
Love1010 Feb. 3 at 4:48 PM
$HURA Going below 20 cents! 100 percent guaranteed.
0 · Reply
Latest News on HURA
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

Feb 2, 2026, 7:45 AM EST - 1 day ago

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

Dec 15, 2025, 7:50 AM EST - 7 weeks ago

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

TuHURA Biosciences Provides Corporate Update Following Recent Financing

Dec 11, 2025, 7:30 AM EST - 7 weeks ago

TuHURA Biosciences Provides Corporate Update Following Recent Financing

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

Dec 9, 2025, 9:49 AM EST - 2 months ago

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

Dec 8, 2025, 7:50 AM EST - 2 months ago

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 14, 2025, 7:00 AM EST - 2 months ago

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:01 AM EST - 3 months ago

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:00 AM EDT - 5 months ago

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14, 2025, 4:15 PM EDT - 6 months ago

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

Jul 10, 2025, 4:00 AM EDT - 7 months ago

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jul 1, 2025, 8:50 AM EDT - 7 months ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

TuHURA Biosciences Completes Acquisition of Kineta

Jun 30, 2025, 8:50 AM EDT - 7 months ago

TuHURA Biosciences Completes Acquisition of Kineta

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

Jun 24, 2025, 8:00 AM EDT - 8 months ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

Jun 23, 2025, 5:00 PM EDT - 8 months ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 9, 2025, 8:00 AM EDT - 8 months ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 3, 2025, 9:58 AM EDT - 8 months ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

Jun 2, 2025, 8:03 AM EDT - 8 months ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 15, 2025, 4:10 PM EDT - 9 months ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 13, 2025, 8:00 AM EDT - 9 months ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

May 5, 2025, 8:00 AM EDT - 9 months ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 10 months ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 10 months ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 7, 2025, 8:24 AM EDT - 10 months ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Apr 1, 2025, 8:00 AM EDT - 11 months ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 11, 2025, 8:05 AM EDT - 11 months ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 9:00 AM EDT - 11 months ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

Dec 20, 2024, 10:18 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Dec 12, 2024, 8:45 AM EST - 1 year ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Nov 25, 2024, 8:35 AM EST - 1 year ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 23, 2024, 8:30 AM EDT - 1 year ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 22, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 17, 2024, 4:35 PM EDT - 1 year ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 12:54 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 16, 2024, 11:58 AM EDT - 1 year ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Sep 20, 2024, 9:25 AM EDT - 1 year ago

Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Sep 18, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Aug 19, 2024, 9:00 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Jul 8, 2024, 6:30 AM EDT - 1 year ago

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

Jul 1, 2024, 8:35 AM EDT - 1 year ago

Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Jun 3, 2024, 8:35 AM EDT - 1 year ago

TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

May 14, 2024, 4:45 PM EDT - 1 year ago

Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

Apr 5, 2024, 1:31 PM EDT - 1 year ago

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

hiletsmakesomemoneyy
hiletsmakesomemoneyy Feb. 4 at 1:04 AM
$HURA Hi brother, not sure what’s your beef with this stock, maybe you are stuck from long time. But let me be very clear, these biotech stock are more of coin flip. Random morning, you are gonna see them pop. Just hold on. I know people like you, will abuse these comments n all. But it’s fine. Our patience is the key to this stock
0 · Reply
hiletsmakesomemoneyy
hiletsmakesomemoneyy Feb. 4 at 1:00 AM
$HURA this is where you have to wait. It’s really a great PR that they released. It takes a week or two to digest among real people.
0 · Reply
Ren_Stimpy
Ren_Stimpy Feb. 3 at 9:07 PM
$HURA Nice!! bought at .4258 and sold for .4660 for a nice 10% profit. Honestly! Was a little nervous at first. When Short sellers are in control they like for SP to be right at 9.9% so they don’t trigger SSR. They failed but still not holding overnight!! Good luck to you all!
0 · Reply
drkazmd65
drkazmd65 Feb. 3 at 8:54 PM
$HURA - Started a small position here this morning,.... Luckily after the 10-11% drop. Obviously, any small pharma that's still got some time to run out on the clinical trials is risky. Sounds like they should have some answers about the candidates and trials sometime during the next year or so,... In the meantime, we wait.
0 · Reply
P_etheris
P_etheris Feb. 3 at 7:37 PM
$HURA Oh, I fooked up on this one… Assessing situation 🤔 First stock in 12 months I bought too high 🤦🏻‍♂️
1 · Reply
TuHURA_IR
TuHURA_IR Feb. 3 at 7:03 PM
$HURA TuHURA Biosciences has received FDA Orphan Drug Designation for IFx 2.0 in the treatment of Stage IIB to Stage IV cutaneous melanoma. This designation reflects the FDA’s recognition of the unmet medical need in this patient population and the potential clinical relevance of IFx 2.0. Orphan Drug Designation provides regulatory incentives that can support development efficiency, including market exclusivity and potential fee reductions. Importantly, this milestone strengthens the regulatory foundation of the IFx platform while Phase 3 development continues in Merkel cell carcinoma. Together, these advances reinforce TuHURA’s strategy of building value through disciplined clinical execution and regulatory alignment.
0 · Reply
TU6637
TU6637 Feb. 3 at 6:51 PM
$HURA they say that all the time On repeat 😂
1 · Reply
michpetr
michpetr Feb. 3 at 5:42 PM
$HURA how could the analysts value this at $10 is beyond my imagination... this runs for r/s.....
0 · Reply
Gotsomescrewsmissing
Gotsomescrewsmissing Feb. 3 at 5:30 PM
$HURA
1 · Reply
Love1010
Love1010 Feb. 3 at 4:48 PM
$HURA Going below 20 cents! 100 percent guaranteed.
0 · Reply
Ren_Stimpy
Ren_Stimpy Feb. 3 at 4:31 PM
Can the bio-nerds from $ALLO $ATON $PGEN $MRNA tell me why $HURA is so hated? Can't find the red flags. What am I missing? https://ir.tuhurabio.com/news-events/presentations
0 · Reply
michpetr
michpetr Feb. 3 at 4:14 PM
$HURA the regular -10% daily back on track.... Stock tanks, pumpers gone..... sad story with this scam here :-(
0 · Reply
Love1010
Love1010 Feb. 3 at 3:23 PM
$HURA This scam artist ran away...reputation gone!
0 · Reply
Love1010
Love1010 Feb. 3 at 3:01 PM
$HURA URGENT: the weekly downward wedge that starts in may 2024 points the fact this stock is going to around 20 cents minimum. Also yesterdays burst was done so players could put on shorts. The stock has at least a 50 percent shave coming. Advise: short or avoid.
0 · Reply
stockobserver
stockobserver Feb. 3 at 2:59 PM
$HURA Down she goes
0 · Reply
stockobserver
stockobserver Feb. 3 at 2:34 PM
$HURA $10 target with an RS maybe
1 · Reply
Gall_t
Gall_t Feb. 3 at 2:04 PM
$HURA now or never 🤯 https://www.tipranks.com/news/the-fly/tuhura-biosciences-price-target-lowered-to-10-from-12-at-h-c-wainwright-thefly
1 · Reply
Fistful_of_Lithium
Fistful_of_Lithium Feb. 3 at 1:22 PM
$HURA
0 · Reply
jayyflash
jayyflash Feb. 3 at 12:10 PM
$HURA Updated News now saying how this is undervalued with 10 dollar rating yet some manipulating short is continuing to short it down with good news. Unbelievable
1 · Reply
Ren_Stimpy
Ren_Stimpy Feb. 3 at 11:49 AM
$HURA reminds me of how $SLS was treated a few years back. Another biotech researching how to treat cancer. Both innovative in their approach and being punished for it by big short sellers. What a shame!!
1 · Reply
Gall_t
Gall_t Feb. 3 at 9:29 AM
$HURA https://www.cancernetwork.com/view/novel-cancer-vaccine-receives-fda-orphan-drug-designation-in-cutaneous-melanoma
0 · Reply
michpetr
michpetr Feb. 3 at 9:28 AM
$HURA 0.3x sooner than expected...? It really has signs of Chinese scam...
0 · Reply